hims - Search News

Hims & Hers, Novo Nordisk

Hosted on MSN · 20h

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational."

MarketWatch on MSN · 1d

Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Wall Street Journal · 1d

Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

Hims & Hers Health, co and food and drug administration

Hims & Hers warns it may stop selling compounded weight-loss drugs

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.

Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

CNBC on MSN · 1d

Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended trading.

22hon MSN

Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

1d

Hims & Hers offers upbeat forecast, but stock slides after hours

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

1d

HIMS Earnings: Shares Sink despite Smashing Guidance Estimates

Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...

3d

HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

ConsumerAffairs21h

Hims & Hers withdraws from Wegovy, Ozempic market

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Fierce Healthcare1d

Hims & Hers projects weight loss business to hit $725M in 2025 despite GLP-1 market shift

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Modern Healthcare1d

Hims & Hers pivots as semaglutide shortage ends

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

HIMS Stock Craters - Is It a Buying Opportunity?

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results